Preemptive Pharmacogenomics Testing Among Geriatric Patients
Launched by GEISINGER CLINIC · Oct 12, 2021
Trial Information
Current as of July 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Pharmacogenomics is the study of how a patient's unique DNA may interact with medications that the patient currently takes or may take in the future. DNA may change how a patient reacts to a medication, such as changing how well it works or the side effects. Knowing a patient's DNA profile may help healthcare professionals select the best medication treatment plan to use. This could include selecting the best medication to give or the medication strength that will work best for the patient. Currently, there is no standard that helps healthcare professionals decide to order a pharmacogenomic...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Follows at a Geisinger 65 Forward clinic location
- • Active prescriptions for 5 or more medications
- Exclusion Criteria:
- • Liver transplantation
- • Allogenic hematopoetic stem cell transplantation
- • Previously enrolled in the Electronic Medical Records and Genomics (eMERGE) pharmacogenomics cohort
About Geisinger Clinic
Geisinger Clinic is a leading healthcare organization based in Pennsylvania, recognized for its commitment to innovative patient care and research. As a clinical trial sponsor, Geisinger Clinic integrates cutting-edge medical research with a focus on improving health outcomes through evidence-based practices. The organization leverages its extensive electronic health record system and diverse patient population to facilitate comprehensive clinical studies that advance medical knowledge and enhance therapeutic options. With a strong emphasis on collaboration and community engagement, Geisinger Clinic aims to translate research findings into practical solutions that benefit patients and the healthcare system as a whole.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Danville, Pennsylvania, United States
Patients applied
Trial Officials
Ryley Uber, Pharm.D.
Principal Investigator
Geisinger Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials